Navigation Links
Sinapis Pharma Announces Frederick Frank as Consultant
Date:9/8/2009

JACKSONVILLE, Fla., Sept. 8 /PRNewswire/ -- Sinapis Pharma, Inc is pleased to announce the addition of Frederick Frank as a consultant to the company. Mr. Frank will leverage his decades of experience to advise the company on merger and acquisition opportunities and fund raising for clinical trial development. Sinapis Pharma has discovered and is patenting a new therapeutic approach to treating stroke in humans using Methamphetamine in an intravenous (IV) formulation.

Mr. Frank will advise Sinapis on its M & A corporate development efforts to find a merger partner for Sinapis as the company conducts its Proof of Concept clinical trial. Sinapis is in discussions with potential pharma partners to form a collaboration that will provide Sinapis funding for its Phase I and IIA clinical trials, while granting the right to acquire Sinapis if the two trials are successful. Sinapis management estimates that the Phase IIA Proof of Concept clinical trial will be complete within approximately twenty-eight (28) months.

Mr. Frank is former Vice Chairman of Lehman Brothers where he spent thirty years building the premier big pharma and healthcare investment banking practice in the U.S. and Europe. Mr. Frank is the leading investment banker internationally for pharmaceutical company mergers, acquisitions and equity fund raising.

Sinapis Pharma, Inc (www.sinapispharma.com) is an early stage drug development company whose lead compound methamphetamine, as an intravenous infusion for the treatment of acute stroke and brain injury, has shown robust pre-clinical efficacy. It is a powerful neuroprotective agent with a remarkable 12 hour therapeutic window in animal studies of stroke. Sinapis CEO Donald Picker, Ph.D. states: "We are thrilled to have Fred Frank join our team at Sinapis. His creativity and depth of relationships in the pharmaceutical industry will be invaluable as we execute our development plan."

For more information contact Dr. Picker at Don.Picker@gmail.com.


'/>"/>
SOURCE Sinapis Pharma, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinapis Pharma To Present at Rodman & Renshaw Conference
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology: